{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T18:40:08Z","timestamp":1748198408652,"version":"3.41.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Advances in oncological therapies have resulted in an increase in the number of patients living with and beyond cancer. The personal and societal impact of chronic pain in the survivor population represents an area of significant unmet need. Capsaicin (a TRPV1 agonist) may provide analgesia with limited systemic side effects. This review looks to summarise the most recent evidence regarding the use of capsaicin in the management of cancer pain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Various international guidelines have recently endorsed the use of high concentration capsaicin patches in the treatment of chronic painful chemotherapy induced peripheral neuropathy. Numerous studies support the use of capsaicin in the treatment of peripheral neuropathic pain. This promising data is predominantly yielded from pain secondary to herpes zoster and diabetic neuropathy, with an expanding but small evidence base for its utility in other neuropathic pains. Emerging data suggests that treatments are better tolerated and provide analgesia more rapidly when compared with systemic treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Whilst randomised controlled trial data in the treatment of cancer pain are lacking, recent large cohort studies, and international guidelines, support the use of high concentration capsaicin patches in a wide variety of neuropathic pain secondary to cancer treatments.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/spc.0000000000000718","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T20:05:16Z","timestamp":1725912316000},"page":"175-180","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Is there a role for capsaicin in cancer pain management?"],"prefix":"10.1097","volume":"18","author":[{"given":"Richard","family":"Gordon-Williams","sequence":"first","affiliation":[{"name":"Pain Medicine Department, The Royal Marsden Hospital, London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Harris","sequence":"additional","affiliation":[{"name":"Pain Medicine Department, The Royal Marsden Hospital, London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5566-1445","authenticated-orcid":false,"given":"David J.","family":"Magee","sequence":"additional","affiliation":[{"name":"Pain Medicine Department, The Royal Marsden Hospital, London"},{"name":"Signalling and Cancer Metabolism Team, Division of Cancer Biology, The Institute of Cancer Research, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"R1-20250525","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","article-title":"Update on prevalence of pain in patients with cancer: systematic review and meta-analysis","volume":"51","author":"Van Den Beuken-Van Everdingen","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"R4-20250525","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/bja\/aex202","article-title":"Pain in cancer survivors; filling in the gaps","volume":"119","author":"Brown","year":"2017","journal-title":"Br J Anaesth"},{"key":"R6-20250525","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/39807","article-title":"The capsaicin receptor: a heat-activated ion channel in the pain pathway","volume":"389","author":"Caterina","year":"1997","journal-title":"Nature"},{"key":"R7-20250525","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1007\/s00520-021-06042-x","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin","volume":"29","author":"Maih\u00f6fner","year":"2021","journal-title":"Support Care Cancer"},{"key":"R8-20250525","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0014-2999(02)01367-5","article-title":"Interaction between vanilloid and glutamate receptors in the central modulation of nociception","volume":"439","author":"Palazzo","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"R9-20250525","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3390\/molecules21070844","article-title":"Capsaicin: current understanding of its mechanisms and therapy of pain and other pre-Clinical and clinical uses","volume":"21","author":"Fattori","year":"2016","journal-title":"Molecules"},{"key":"R10-20250525","doi-asserted-by":"crossref","first-page":"ra15","DOI":"10.1126\/scisignal.2005667","article-title":"Activation of TRPV1 channels inhibits mechanosensitive Piezo channel activity by depleting membrane phosphoinositides","volume":"8","author":"Borbiro","year":"2015","journal-title":"Sci Signal"},{"key":"R11-20250525","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.1523\/JNEUROSCI.18-21-08947.1998","article-title":"Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function","volume":"18","author":"Simone","year":"1998","journal-title":"J Neurosci"},{"key":"R12-20250525","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/JPR.S395065","article-title":"The preemptive analgesic effect of capsaicin involves attenuations of epidermal keratinocytes proliferation and expression of pro-inflammatory mediators after plantar incision in rats","volume":"16","author":"Guo","year":"2023","journal-title":"J Pain Res"},{"key":"R13-20250525","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann Oncol"},{"key":"R14-20250525","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/pn-2022-003444","article-title":"Toxic neuropathies: a practical approach","volume":"23","author":"Smyth","year":"2023","journal-title":"Pract Neurol"},{"key":"R15-20250525","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2018.03.052","article-title":"Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: a longitudinal study","volume":"149","author":"Bonhof","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R16-20250525","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/toxics11020104","article-title":"Self-reported assessment of the socio-economic impact of anticancer chemotherapy-related neurotoxicity","volume":"11","author":"Cavaletti","year":"2023","journal-title":"Toxics"},{"key":"R17-20250525","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/2193-1801-3-366","article-title":"Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience","volume":"3","author":"Bhatnagar","year":"2014","journal-title":"Springerplus"},{"key":"R18-20250525","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s10147-011-0352-x","article-title":"Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer","volume":"18","author":"Tanabe","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"R19-20250525","doi-asserted-by":"crossref","first-page":"15347354231185110","DOI":"10.1177\/15347354231185110","article-title":"Neurological outcomes of chemotherapy-induced peripheral neuropathy in patients with cancer: a systematic review and meta-analysis","volume":"22","author":"Suzuki","year":"2023","journal-title":"Integr Cancer Ther"},{"key":"R20-20250525","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.expneurol.2006.05.007","article-title":"Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells","volume":"201","author":"Siau","year":"2006","journal-title":"Exp Neurol"},{"key":"R21-20250525","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1213\/01.ane.0000204318.35194.ed","article-title":"Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy","volume":"102","author":"Siau","year":"2006","journal-title":"Anesth Analg"},{"key":"R22-20250525","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jpain.2008.01.335","article-title":"Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy","volume":"9","author":"Joseph","year":"2008","journal-title":"J Pain"},{"key":"R23-20250525","doi-asserted-by":"crossref","first-page":"1744806918816462","DOI":"10.1177\/1744806918816462","article-title":"Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors","volume":"14","author":"Kober","year":"2018","journal-title":"Mol Pain"},{"key":"R24-20250525","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1744-8069-6-15","article-title":"Transient receptor potential vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice","volume":"6","author":"Ta","year":"2010","journal-title":"Mol Pain"},{"key":"R25-20250525","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"R26-20250525","doi-asserted-by":"crossref","first-page":"e0123866","DOI":"10.1371\/journal.pone.0123866","article-title":"Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy","volume":"10","author":"Minarik","year":"2015","journal-title":"PLoS One"},{"key":"R27-20250525","doi-asserted-by":"crossref","first-page":"e16285","DOI":"10.1111\/ene.16285","article-title":"Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy","volume":"31","author":"Matthys","year":"2024","journal-title":"Eur J Neurol"},{"key":"R28-20250525","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jpain.2016.09.008","article-title":"Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study","volume":"18","author":"Simpson","year":"2017","journal-title":"J Pain"},{"key":"R29-20250525","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.2147\/JPR.S213912","article-title":"Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification","volume":"12","author":"Anand","year":"2019","journal-title":"J Pain Res"},{"key":"R30-20250525","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1185\/03007995.2013.792246","article-title":"Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study","volume":"29","author":"Maihofner","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"R31-20250525","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3390\/cancers15020349","article-title":"Evaluation of 8% capsaicin patches in chemotherapy-induced peripheral neuropathy: a retrospective study in a comprehensive cancer center","volume":"15","author":"Bienfait","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R32-20250525","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/j.pain.0000000000000753","article-title":"Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles","volume":"158","author":"Baron","year":"2017","journal-title":"Pain"},{"key":"R33-20250525","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3892\/mmr.2024.13162","article-title":"Pharmacological activity of capsaicin: mechanisms and controversies (Review)","volume":"29","author":"Zhang","year":"2024","journal-title":"Mol Med Rep"},{"key":"R34-20250525","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/20494637231201502","article-title":"Topical capsaicin 8% patch in peripheral neuropathic pain: efficacy and quality of life","volume":"18","author":"Santos","year":"2024","journal-title":"Br J Pain"},{"key":"R35-20250525","doi-asserted-by":"crossref","first-page":"998904","DOI":"10.3389\/fneur.2022.998904","article-title":"Reversing painful and non-painful diabetic neuropathy with the capsaicin 8% patch: clinical evidence for pain relief and restoration of function via nerve fiber regeneration","volume":"13","author":"Anand","year":"2022","journal-title":"Front Neurol"},{"key":"R36-20250525","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/bjc.2017.124","article-title":"Herpes zoster risk after 21 specific cancers: population-based case-control study","volume":"116","author":"Hansson","year":"2017","journal-title":"Br J Cancer"},{"key":"R37-20250525","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3390\/curroncol28040237","article-title":"The association between herpes zoster and increased cancer risk: a nationwide population-based matched control study","volume":"28","author":"Sim","year":"2021","journal-title":"Curr Oncol"},{"key":"R38-20250525","doi-asserted-by":"crossref","first-page":"2167907","DOI":"10.1080\/21645515.2023.2167907","article-title":"Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer","volume":"19","author":"Curran","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"R39-20250525","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(08)70228-X","article-title":"NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study","volume":"7","author":"Backonja","year":"2008","journal-title":"Lancet Neurol"},{"key":"R40-20250525","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jpain.2010.01.270","article-title":"A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia","volume":"11","author":"Webster","year":"2010","journal-title":"J Pain"},{"key":"R41-20250525","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/papr.13345","article-title":"Characteristics and outcomes of peripheral neuropathic pain patients with repeated applications of high-concentration capsaicin cutaneous patch: results of a retrospective chart review in Germany","volume":"24","author":"Kern","year":"2024","journal-title":"Pain Pract"},{"key":"R42-20250525","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S0140-6736(06)68700-X","article-title":"Persistent postsurgical pain: risk factors and prevention","volume":"367","author":"Kehlet","year":"2006","journal-title":"Lancet"},{"key":"R43-20250525","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pain.2012.09.010","article-title":"The neuropathic component in persistent postsurgical pain: a systematic literature review","volume":"154","author":"Haroutiunian","year":"2013","journal-title":"Pain"},{"key":"R44-20250525","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1212\/01.wnl.0000259085.61898.9e","article-title":"The impact of neuropathic pain on health-related quality of life: review and implications","volume":"68","author":"Jensen","year":"2007","journal-title":"Neurology"},{"key":"R45-20250525","first-page":"CD007393","article-title":"Topical capsaicin (high concentration) for chronic neuropathic pain in adults","volume":"1","author":"Derry","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R46-20250525","doi-asserted-by":"crossref","first-page":"e109144","DOI":"10.1371\/journal.pone.0109144","article-title":"A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial","volume":"9","author":"Bischoff","year":"2014","journal-title":"PLoS One"},{"key":"R47-20250525","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ejp.731","article-title":"Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain","volume":"20","author":"Haanp\u00e4\u00e4","year":"2016","journal-title":"Eur J Pain"},{"key":"R48-20250525","doi-asserted-by":"crossref","first-page":"afac205","DOI":"10.1093\/ageing\/afac205","article-title":"World guidelines for falls prevention and management for older adults: a global initiative","volume":"51","author":"Montero-Odasso","year":"2022","journal-title":"Age Ageing"},{"key":"R49-20250525","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/JPR.S341378","article-title":"Peripheral neuropathic pain following breast cancer: effectiveness and tolerability of high-concentration capsaicin patch","volume":"15","author":"Dupoiron","year":"2022","journal-title":"J Pain Res"},{"key":"R50-20250525","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/ejp.1155","article-title":"Superiority of capsaicin 8% patch versus oral pregabalin on dynamic mechanical allodynia in patients with peripheral neuropathic pain","volume":"22","author":"Cruccu","year":"2018","journal-title":"Eur J Pain"},{"key":"R51-20250525","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jdcr.2022.09.032","article-title":"Capsaicin 8% patch as therapy for neuropathic chronic postsurgical pain after melanoma excision surgery: a single center case series","volume":"30","author":"Laude-Pagniez","year":"2022","journal-title":"JAAD Case Rep"},{"key":"R52-20250525","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bone.2019.03.040","article-title":"TRPV1 activation alters the function of A\u03b4 and C fiber sensory neurons that innervate bone","volume":"123","author":"Morgan","year":"2019","journal-title":"Bone"},{"key":"R53-20250525","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1523\/JNEUROSCI.3815-04.2005","article-title":"Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain","volume":"25","author":"Ghilardi","year":"2005","journal-title":"J Neurosci"},{"key":"R54-20250525","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12264-012-1211-0","article-title":"Formaldehyde up-regulates TRPV1 through MAPK and PI3K signaling pathways in a rat model of bone cancer pain","volume":"28","author":"Han","year":"2012","journal-title":"Neurosci Bull"},{"key":"R55-20250525","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1097\/j.pain.0000000000000158","article-title":"Interleukin-6-mediated functional upregulation of TRPV1 receptors in dorsal root ganglion neurons through the activation of JAK\/PI3K signaling pathway roles in the development of bone cancer pain in a rat model","volume":"156","author":"Fang","year":"2015","journal-title":"Pain"},{"key":"R56-20250525","first-page":"51","article-title":"New mechanism of bone cancer pain: tumor tissue-derived endogenous formaldehyde induced bone cancer pain via TRPV1 activation","volume":"904","author":"Wan","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"R57-20250525","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1080\/01616412.2019.1639317","article-title":"AAV-mediated siRNA against TRPV1 reduces nociception in a rat model of bone cancer pain","volume":"41","author":"Zhang","year":"2019","journal-title":"Neurol Res"},{"key":"R58-20250525","first-page":"177","article-title":"Intrathecal Resiniferatoxin for medication-refractory pain in advanced cancer","volume":"87","author":"Pomeraniec","year":"2020","journal-title":"Neurosurgery"},{"key":"R59-20250525","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of Chemotherapy-Induced Peripheral Neuropathy in survivors of adult cancers: ASCO Guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"key":"R60-20250525","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1186\/s12885-022-10348-2","article-title":"Study protocol of the TEC-ORL clinical trial: a randomized comparative phase II trial investigating the analgesic activity of capsaicin vs Laroxyl in head and neck Cancer survivors presenting with neuropathic pain sequelae","volume":"22","author":"Boden","year":"2022","journal-title":"BMC Cancer"},{"key":"R61-20250525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2023\/7708982","article-title":"The Pelican Investigators Team: considerations on the obstacles that lead to slow recruitment in a pain management clinical trial: experiences from the Belgian PELICAN (PrEgabalin LIdocaine CApsaicin Neuropathic pain) pragmatic study","volume":"2023","author":"Hans","year":"2023","journal-title":"Pain Res Manag"},{"key":"R63-20250525","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1093\/pm\/pnab113","article-title":"Progressive response to repeat application of Capsaicin 179 mg (8% w\/w) cutaneous patch in peripheral neuropathic pain: comprehensive new analysis and clinical implications","volume":"22","author":"Freynhagen","year":"2021","journal-title":"Pain Med"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T18:04:20Z","timestamp":1748196260000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000718","relation":{},"ISSN":["1751-4258","1751-4266"],"issn-type":[{"type":"print","value":"1751-4258"},{"type":"electronic","value":"1751-4266"}],"subject":[],"published":{"date-parts":[[2024,10,30]]}}}